Of	O
the	O
344	O
wounded	O
that	O
were	O
admitted	O
to	O
the	O
Tripler	O
Army	O
Hospital	O
,	O
only	O
13	O
did	O
not	O
survive	O
,	O
and	O
it	O
is	O
unlikely	O
that	O
thiopentone	other-medical
overdose	O
was	O
responsible	O
for	O
more	O
than	O
a	O
few	O
of	O
these	O
.	O

Likewise	O
in	O
the	O
2000	O
US	O
APL	O
study	O
,	O
the	O
survival	O
rates	O
in	O
those	O
receiving	O
ATRA	other-medical
maintenance	O
was	O
61	O
%	O
compared	O
to	O
just	O
36	O
%	O
without	O
ATRA	other-medical
maintenance	O
.	O

Many	O
of	O
these	O
substances	O
,	O
far	O
from	O
contributing	O
to	O
longevity	O
,	O
were	O
actively	O
toxic	O
and	O
resulted	O
in	O
Chinese	O
alchemical	O
elixir	other-medical
poisoning	O
.	O

Prontosil	other-medical
was	O
the	O
first	O
commercially	O
available	O
antibacterial	other-medical
antibiotic	other-medical
(	O
with	O
a	O
relatively	O
broad	O
effect	O
against	O
Gram-positive	O
cocci	O
.	O

Naltrexone	other-medical
is	O
an	O
opioid	other-medical
receptor	other-medical
antagonist	other-medical
used	O
for	O
the	O
treatment	O
of	O
opioid	other-medical
addiction	other-medical
.	O

Unlike	O
aspirin	other-medical
,	O
it	O
is	O
safe	O
for	O
children	O
,	O
as	O
paracetamol	other-medical
is	O
not	O
associated	O
with	O
a	O
risk	O
of	O
Reye	O
's	O
syndrome	O
in	O
children	O
with	O
viral	O
illnesses	O
.	O

A	O
large	O
cohort	O
study	O
in	O
Denmark	O
found	O
,	O
in	O
addition	O
,	O
no	O
association	O
between	O
metoclopramide	other-medical
exposure	O
and	O
miscarriage	O
.	O

In	O
clinical	O
setting	O
,	O
the	O
mutations	O
in	O
either	O
the	O
thymidine	O
kinase	O
gene	O
or	O
DNA	O
polymerase	O
gene	O
has	O
caused	O
resistance	O
to	O
aciclovir	other-medical
.	O

However	O
,	O
individuals	O
with	O
X-linked	O
thrombocytopenia	O
have	O
an	O
increased	O
risk	O
for	O
life-threatening	O
brain	other-medical
hemorrhages	other-medical
and	O
spontaneous	other-medical
bleeding	other-medical
.	O

These	O
mutants	O
also	O
demonstrated	O
diminished	O
dopamine	O
binding	O
affinity	O
,	O
reduced	O
cell	O
surface	O
transporter	O
,	O
loss	O
of	O
post-translational	O
dopamine	O
transporter	O
glycosylation	O
,	O
and	O
failure	O
of	O
amphetamine	other-medical
-mediated	O
dopamine	O
efflux	O
.	O

The	O
KRAS	O
gene	O
encodes	O
a	O
small	O
G	O
protein	O
on	O
the	O
EGFR	other-medical
pathway	O
.	O

Clomethiazole	other-medical
acts	O
as	O
a	O
positive	O
allosteric	O
modulator	O
at	O
the	O
barbiturate	O
/	O
picrotoxin	O
site	O
of	O
the	O
GABAA	O
receptor	O
.	O

For	O
his	O
suggestions	O
on	O
the	O
cure	O
of	O
varicocele	O
and	O
on	O
the	O
operation	O
of	O
urethroplasty	other-medical
he	O
received	O
in	O
1842	O
one	O
of	O
the	O
Montyon	O
prizes	O
.	O

The	O
WHO	O
announced	O
it	O
was	O
developing	O
a	O
COVID-19	other-medical
virus	other-medical
treatment	O
master	O
plan	O
.	O

As	O
such	O
,	O
antibodies	O
against	O
HER2/neu	O
have	O
been	O
FDA	O
approved	O
for	O
clinical	O
treatment	O
of	O
cancer	O
under	O
the	O
drug	O
name	O
``	O
Herceptin	other-medical
``	O
.	O

Bumetanide	other-medical
is	O
a	O
loop	other-medical
diuretic	other-medical
(	O
water	O
pill	O
)	O
that	O
prevents	O
your	O
body	O
from	O
absorbing	O
too	O
much	O
salt	O
,	O
allowing	O
the	O
salt	O
to	O
instead	O
be	O
passed	O
in	O
your	O
urine	O
.	O

Immune-mediated	O
HIT	O
most	O
commonly	O
arises	O
five	O
to	O
ten	O
days	O
after	O
exposure	O
to	O
heparin	other-medical
.	O

In	O
addition	O
he	O
had	O
signs	O
of	O
Balint	O
's	O
syndrome	O
(	O
mild	other-medical
simultanagnosia	other-medical
,	O
optic	other-medical
ataxia	other-medical
,	O
and	O
optic	other-medical
apraxia	other-medical
)	O
.	O

In	O
humans	O
,	O
tolerance	O
to	O
the	O
anticonvulsant	O
effects	O
of	O
clonazepam	other-medical
occurs	O
frequently	O
.	O

As	O
of	O
2006	O
,	O
quinine	other-medical
is	O
no	O
longer	O
recommended	O
by	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
as	O
a	O
first-line	O
treatment	O
for	O
malaria	O
,	O
because	O
there	O
are	O
other	O
substances	O
that	O
are	O
equally	O
effective	O
with	O
fewer	O
side	O
effects	O
.	O

These	O
mechanisms	O
of	O
STAT3-RANTES	O
autocrine	O
signaling	O
suggest	O
a	O
novel	O
strategy	O
for	O
management	O
of	O
patients	O
with	O
tamoxifen-resistant	other-medical
tumors	O
.	O

Research	O
continued	O
,	O
further	O
fueled	O
by	O
knowledge	O
gained	O
from	O
other	O
techniques	O
like	O
TMS	other-medical
and	O
fMRI	other-medical
.	O

A	O
formulation	O
of	O
MPA	other-medical
as	O
an	O
aqueous	O
suspension	O
for	O
subcutaneous	O
injection	O
is	O
also	O
available	O
in	O
the	O
United	O
States	O
under	O
the	O
brand	O
name	O
Depo-SubQ	other-medical
Provera	other-medical
104	other-medical
.	O

Influvac	other-medical
is	O
a	O
subunit	O
vaccine	O
produced	O
and	O
marketed	O
by	O
Mylan	O
.	O

From	O
1975	O
to	O
1984	O
,	O
he	O
was	O
one	O
of	O
the	O
main	O
ringleaders	O
of	O
a	O
US	O
$	O
1.65	O
billion	O
heroin	other-medical
trafficking	O
operation	O
,	O
known	O
as	O
the	O
Pizza	O
Connection	O
,	O
that	O
imported	O
heroin	other-medical
from	O
the	O
Middle	O
East	O
and	O
distributed	O
the	O
drugs	O
through	O
U.S	O
.	O
mid-western	O
pizzeria	O
store	O
fronts	O
.	O

Treatments	O
for	O
angina	O
are	O
balloon	other-medical
angioplasty	other-medical
,	O
in	O
which	O
the	O
balloon	other-medical
is	O
inserted	O
at	O
the	O
end	O
of	O
a	O
catheter	other-medical
and	O
inflated	O
to	O
widen	O
the	O
arterial	O
lumen	O
.	O

Type	O
2	O
diabetes	O
is	O
a	O
progressive	O
condition	O
in	O
which	O
the	O
body	O
becomes	O
resistant	O
to	O
the	O
normal	O
effects	O
of	O
insulin	other-medical
and/or	O
gradually	O
loses	O
the	O
capacity	O
to	O
produce	O
enough	O
insulin	other-medical
in	O
the	O
pancreas	O
.	O

Gardasil	other-medical
protects	O
against	O
strains	O
6	O
,	O
11	O
,	O
16	O
,	O
and	O
18	O
,	O
and	O
Cervarix	other-medical
protects	O
against	O
16	O
and	O
18	O
,	O
whereas	O
plantar	O
warts	O
are	O
caused	O
by	O
strains	O
1	O
,	O
2	O
,	O
4	O
,	O
and	O
63	O
.	O

It	O
is	O
thought	O
that	O
Ro15-4513	other-medical
antagonizes	O
the	O
effects	O
of	O
ethanol	O
because	O
the	O
azido	O
group	O
at	O
the	O
8-	O
position	O
of	O
the	O
benzene	O
ring	O
blocks	O
the	O
binding	O
site	O
for	O
ethanol	O
on	O
the	O
α5β3δ	O
subtype	O
of	O
the	O
GABAA	O
receptor	O
;	O
flumazenil	other-medical
,	O
which	O
has	O
a	O
fluorine	O
at	O
this	O
position	O
,	O
does	O
not	O
block	O
this	O
binding	O
site	O
and	O
so	O
does	O
not	O
counteract	O
the	O
effects	O
of	O
ethanol	O
.	O

Multiple	O
studies	O
have	O
found	O
docusate	other-medical
to	O
be	O
no	O
more	O
effective	O
than	O
a	O
placebo	O
for	O
improving	O
constipation	O
.	O

Pathogenesis	O
of	O
immune-mediated	O
HIT	O
is	O
believed	O
to	O
be	O
caused	O
by	O
heparin	other-medical
-dependent	O
immunoglobulin	O
antibodies	O
binding	O
to	O
platelet	O
factor	O
4/	O
heparin	other-medical
complexes	O
on	O
platelets	O
,	O
leading	O
to	O
wide	O
spread	O
platelet	O
activation	O
.	O

Gaetano	O
Badalamenti	O
would	O
become	O
one	O
of	O
the	O
major	O
heroin	other-medical
traffickers	O
of	O
the	O
Sicilian	O
Mafia	O
.	O

Melatonin	other-medical
has	O
been	O
claimed	O
to	O
be	O
an	O
endogenous	O
ligand	O
for	O
ROR-α	O
while	O
CGP	O
52608	O
has	O
been	O
identified	O
as	O
a	O
ROR-α	O
selective	O
synthetic	O
ligand	O
.	O

Along	O
with	O
other	O
brands	O
,	O
Anadin	other-medical
's	other-medical
paracetamol	other-medical
tablets	other-medical
have	O
been	O
criticised	O
for	O
being	O
overpriced	O
compared	O
to	O
non-branded	O
versions	O
(	O
e.g	O
.	O

Testimony	O
then	O
turned	O
to	O
the	O
use	O
of	O
flumazenil	other-medical
(	O
a	O
benzodiazepine	other-medical
antagonist	O
)	O
as	O
an	O
antidote	O
to	O
Ativan	other-medical
.	O

However	O
,	O
in	O
part	O
due	O
to	O
bad	O
publicity	O
from	O
its	O
illicit	O
use	O
by	O
bodybuilders	O
,	O
production	O
of	O
Anavar	other-medical
was	O
discontinued	O
by	O
Searle	O
Laboratories	O
in	O
1989	O
.	O

For	O
people	O
who	O
have	O
already	O
had	O
a	O
single	O
DVT	O
event	O
,	O
the	O
best	O
way	O
to	O
prevent	O
a	O
second	O
DVT	O
is	O
appropriate	O
anticoagulation	other-medical
therapy	other-medical
.	O

Epinephrine	other-medical
is	O
the	O
drug	O
of	O
choice	O
for	O
treating	O
anaphylaxis	O
.	O

However	O
,	O
because	O
this	O
is	O
thought	O
to	O
be	O
mediated	O
by	O
the	O
effect	O
of	O
omeprazole	other-medical
and	O
esomeprazole	other-medical
on	O
CYP2C19	O
,	O
the	O
enzyme	O
that	O
activates	O
clopidogrel	O
,	O
this	O
drug	O
interaction	O
is	O
not	O
expected	O
to	O
occur	O
as	O
strongly	O
with	O
rabeprazole	other-medical
.	O

Radiation	other-medical
therapy	other-medical
is	O
generally	O
used	O
for	O
people	O
whose	O
tumors	O
are	O
not	O
completely	O
removed	O
by	O
surgery	O
,	O
for	O
people	O
who	O
are	O
not	O
good	O
candidates	O
for	O
surgery	O
because	O
of	O
other	O
health	O
problems	O
,	O
and	O
for	O
people	O
who	O
do	O
not	O
respond	O
adequately	O
to	O
surgery	O
and	O
medication	O
.	O

It	O
is	O
native	O
to	O
northern	O
Nigeria	O
,	O
where	O
local	O
farmers	O
extract	O
its	O
latex	O
for	O
use	O
as	O
a	O
pesticide	other-medical
.	O

Tazarotene	other-medical
is	O
the	O
most	O
effective	O
and	O
expensive	O
topical	other-medical
retinoid	other-medical
but	O
is	O
not	O
as	O
well	O
tolerated	O
.	O

Intermittent	other-medical
urinary	other-medical
catheterization	other-medical
is	O
used	O
to	O
relieve	O
the	O
bladder	O
in	O
people	O
with	O
urinary	O
retention	O
.	O

Hyperventilation	other-medical
may	O
occur	O
and	O
is	O
sometimes	O
followed	O
by	O
apnea	other-medical
and	O
cyanosis	other-medical
.	O

The	O
players	O
and	O
their	O
attorneys	O
alleged	O
that	O
the	O
League	O
failed	O
to	O
properly	O
treat	O
head	O
injuries	O
in	O
spite	O
of	O
prevailing	O
medical	O
evidence	O
and	O
the	O
prevalent	O
use	O
of	O
Toradol	other-medical
administered	O
by	O
the	O
team	O
to	O
the	O
players	O
as	O
a	O
pain-masking	O
agent	O
,	O
leading	O
the	O
players	O
to	O
develop	O
effects	O
of	O
brain	O
injury	O
.	O

An	O
example	O
of	O
its	O
use	O
as	O
a	O
protecting	O
group	O
in	O
a	O
complex	O
organic	O
synthesis	O
is	O
the	O
Nicolaou	other-medical
Taxol	other-medical
total	O
synthesis	O
.	O

Bevacizumab	other-medical
can	O
also	O
be	O
combined	O
with	O
platinum	other-medical
chemotherapy	other-medical
,	O
a	O
combination	O
that	O
has	O
had	O
positive	O
preliminary	O
results	O
in	O
PFS	O
,	O
but	O
equivocal	O
results	O
regarding	O
overall	O
survival	O
.	O

It	O
fully	O
substitutes	O
for	O
MBDB	other-medical
but	O
not	O
amphetamine	other-medical
in	O
trained	O
animals	O
,	O
though	O
it	O
does	O
produce	O
disruption	O
for	O
the	O
latter	O
at	O
high	O
doses	O
.	O

It	O
lasts	O
longer	O
than	O
lansoprazole	other-medical
,	O
to	O
which	O
it	O
is	O
chemically	O
related	O
,	O
and	O
needs	O
to	O
be	O
taken	O
less	O
often	O
.	O

Postradioembolization	O
syndrome	O
(	O
PRS	O
)	O
includes	O
fatigue	other-medical
,	O
nausea	other-medical
,	O
vomiting	other-medical
,	O
abdominal	other-medical
discomfort	other-medical
or	O
pain	other-medical
,	O
and	O
cachexia	other-medical
,	O
occurring	O
in	O
20-70	O
%	O
of	O
patients	O
.	O

Some	O
of	O
the	O
newer	O
psychiatric	O
medications	O
,	O
such	O
as	O
Zyprexa	other-medical
(	O
Olanzapine	other-medical
)	O
and	O
Cymbalta	other-medical
(	O
Duloxetine	other-medical
)	O
,	O
can	O
also	O
cause	O
significant	O
hyperglycemia	O
.	O

Emergency	other-medical
contraception	other-medical
was	O
being	O
developed	O
and	O
produced	O
by	O
Hoechst	O
under	O
the	O
name	O
RU-486	other-medical
.	O

Individuals	O
diagnosed	O
with	O
PD	O
often	O
exhibit	O
similar	O
movement	other-medical
dysfunction	other-medical
as	O
those	O
diagnosed	O
with	O
CBD	O
,	O
which	O
adds	O
complexity	O
to	O
its	O
diagnosis	O
.	O

Similarly	O
to	O
most	O
other	O
opioids	O
,	O
oxycodone	other-medical
increases	O
prolactin	O
secretion	O
,	O
but	O
its	O
influence	O
on	O
testosterone	O
levels	O
is	O
unknown	O
.	O

This	O
serves	O
as	O
evidence	O
for	O
the	O
idea	O
FITM2	O
is	O
functionally	O
regulated	O
by	O
PPAR	other-medical
γ	other-medical
.	O

Thiopental	other-medical
is	O
famously	O
associated	O
with	O
a	O
number	O
of	O
anesthetic	O
deaths	O
in	O
victims	O
of	O
the	O
attack	O
on	O
Pearl	O
Harbor	O
.	O

Several	O
internal	O
documents	O
,	O
which	O
were	O
released	O
by	O
the	O
British	O
Medical	O
Journal	O
,	O
indicated	O
a	O
link	O
between	O
use	O
of	O
Prozac	other-medical
and	O
suicidal	O
or	O
violent	O
behavior	O
.	O

Doctors	O
frequently	O
prescribed	O
morphine	other-medical
to	O
women	O
in	O
those	O
years	O
to	O
treat	O
a	O
variety	O
of	O
causes	O
,	O
and	O
researchers	O
believe	O
that	O
her	O
symptoms	O
could	O
have	O
been	O
from	O
morphine	other-medical
poisoning	O
.	O

In	O
insulin-dependent	O
diabetic	O
people	O
,	O
this	O
phenomenon	O
is	O
termed	O
hypoglycemia	other-medical
unawareness	O
,	O
and	O
is	O
a	O
significant	O
clinical	O
problem	O
when	O
improved	O
glycemic	O
control	O
is	O
attempted	O
.	O

Haloperidol	other-medical
is	O
also	O
used	O
on	O
many	O
different	O
kinds	O
of	O
animals	O
for	O
nonselective	O
tranquilization	O
and	O
diminishing	O
behavioral	O
arousal	O
,	O
in	O
veterinary	O
and	O
other	O
settings	O
including	O
captivity	O
management	O
.	O

Additionally	O
,	O
dosing	O
naltrexone	other-medical
after	O
recent	O
opioid	other-medical
use	O
could	O
lead	O
to	O
precipitated	other-medical
withdrawal	other-medical
.	O

Segal	O
suggested	O
an	O
HIV	O
therapy	O
of	O
anti-inflammatory	O
aspirin	other-medical
or	O
ultraviolet	other-medical
radiation	other-medical
of	O
the	O
patient	O
's	O
blood	O
in	O
order	O
to	O
reduce	O
the	O
metabolic	O
activity	O
of	O
macrophages	O
,	O
which	O
are	O
host	O
cells	O
for	O
HIV	O
.	O

There	O
is	O
some	O
evidence	O
that	O
omeprazole	other-medical
and	O
esomeprazole	other-medical
,	O
two	O
medications	O
in	O
the	O
same	O
class	O
as	O
rabeprazole	other-medical
,	O
can	O
disturb	O
the	O
conversion	O
of	O
an	O
anticoagulant	O
medication	O
called	O
clopidogrel	other-medical
to	O
its	O
active	O
metabolite	O
.	O

His	O
early	O
work	O
focused	O
on	O
premature	O
ejaculation	O
and	O
erectile	O
dysfunction	O
,	O
and	O
he	O
has	O
written	O
on	O
a	O
number	O
of	O
treatment	O
options	O
,	O
including	O
vacuum	other-medical
pumps	other-medical
,	O
injections	other-medical
into	other-medical
the	other-medical
corpus	other-medical
cavernosum	other-medical
of	other-medical
the	other-medical
penis	other-medical
,	O
and	O
Viagra	other-medical
.	O

Botulinum	other-medical
toxin	other-medical
type-A	other-medical
is	O
only	O
temporary	O
and	O
repeated	O
injections	O
need	O
to	O
take	O
place	O
in	O
order	O
to	O
feel	O
the	O
effects	O
.	O

Rotigotine	other-medical
behaves	O
as	O
a	O
partial	O
or	O
full	O
agonist	O
(	O
depending	O
on	O
the	O
assay	O
)	O
at	O
all	O
dopamine	O
receptors	O
listed	O
,	O
as	O
an	O
antagonist	O
at	O
the	O
α2B-adrenergic	O
receptor	O
,	O
and	O
as	O
a	O
partial	O
agonist	O
at	O
the	O
5-HT1A	O
receptor	O
.	O

The	O
neuraminidase	O
inhibitors	O
oseltamivir	other-medical
and	O
zanamivir	other-medical
were	O
approved	O
in	O
the	O
US	O
and	O
Europe	O
for	O
treatment	O
and	O
prevention	O
of	O
influenza	O
A	O
and	O
B.	O
Peramivir	O
acts	O
by	O
strongly	O
binding	O
to	O
the	O
neuraminidase	O
of	O
the	O
influenza	O
viruses	O
and	O
inhibits	O
activation	O
of	O
neuraminidase	O
much	O
longer	O
than	O
Oseltamivir	other-medical
or	O
Zanamivir	other-medical
.	O

Furosemide	other-medical
,	O
sold	O
under	O
the	O
brand	O
name	O
Lasix	O
among	O
others	O
,	O
is	O
a	O
loop	O
diuretic	O
medication	O
used	O
to	O
treat	O
fluid	O
build-up	O
due	O
to	O
heart	O
failure	O
,	O
liver	O
scarring	O
,	O
or	O
kidney	O
disease	O
.	O

These	O
substances	O
are	O
called	O
nootropics	other-medical
and	O
can	O
potentially	O
benefit	O
individuals	O
with	O
cognitive	O
decline	O
and	O
many	O
different	O
disorders	O
,	O
but	O
may	O
also	O
be	O
capable	O
of	O
yielding	O
results	O
in	O
cognitively	O
healthy	O
persons	O
.	O

Rates	O
of	O
sexual	O
dysfunction	O
in	O
MDD	O
patients	O
treated	O
with	O
duloxetine	other-medical
vs	O
escitalopram	other-medical
did	O
not	O
differ	O
significantly	O
at	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
of	O
treatment	O
,	O
although	O
the	O
trend	O
favored	O
duloxetine	other-medical
(	O
33.3	O
%	O
of	O
duloxetine	other-medical
patients	O
experienced	O
sexual	O
side	O
effects	O
compared	O
to	O
43.6	O
%	O
of	O
those	O
receiving	O
escitalopram	other-medical
and	O
25	O
%	O
of	O
those	O
receiving	O
placebo	other-medical
)	O
.	O

A	O
landmark	O
study	O
found	O
that	O
fluoxetine	O
(	O
Prozac	other-medical
)	O
was	O
more	O
likely	O
to	O
increase	O
overall	O
suicidal	O
behavior	O
.	O

Hyoscine	other-medical
butylbromide	other-medical
can	O
be	O
taken	O
by	O
mouth	O
,	O
injection	O
into	O
a	O
muscle	O
,	O
or	O
into	O
a	O
vein	O
.	O

Testosterone	other-medical
enanthate	other-medical
can	O
also	O
lead	O
to	O
an	O
increase	O
in	O
igf-1	O
and	O
igf-bp	O
.	O

``	O
Prototheca	O
zopfii	O
``	O
is	O
less	O
susceptible	O
or	O
completely	O
resistant	O
to	O
clotrimazole	other-medical
,	O
fluconazole	other-medical
,	O
econazole	other-medical
,	O
flucytosine	other-medical
,	O
cefoperazone	other-medical
,	O
cephalexin	other-medical
,	O
enrofloxacin	other-medical
,	O
lincomycin	other-medical
,	O
oxytetracycline	other-medical
,	O
miconazole	other-medical
,	O
colistin	other-medical
,	O
a	O
combination	O
of	O
amoxicillin	other-medical
with	O
clavulanic	other-medical
acid	other-medical
,	O
enrofloxacin	other-medical
,	O
amoxicillin	other-medical
,	O
tetracycline	other-medical
,	O
penicillin	other-medical
,	O
lincomycin	other-medical
,	O
and	O
novobiocin	other-medical
,	O
whereas	O
drugs	O
such	O
as	O
nystatin	other-medical
,	O
ketoconazole	other-medical
,	O
and	O
amphotericin	other-medical
B	other-medical
are	O
effective	O
against	O
algae	O
isolated	O
from	O
milk	O
of	O
mastitis-affected	other-medical
cows	O
.	O

CNS	other-medical
behavioral	O
changes	O
such	O
as	O
chronic	O
fatigue	O
and	O
depression	O
occur	O
in	O
patients	O
who	O
are	O
undergoing	O
irradiation	O
for	O
cancer	O
therapy	O
.	O

Methicillin	other-medical
was	O
then	O
the	O
antibiotic	O
of	O
choice	O
,	O
but	O
has	O
since	O
been	O
replaced	O
by	O
oxacillin	other-medical
because	O
of	O
significant	O
kidney	O
toxicity	O
.	O

Fistulas	O
can	O
result	O
from	O
incorrectly	O
positioned	O
equipment	O
,	O
high	O
cuff	O
pressures	O
causing	O
pressure	O
sores	O
or	O
mucosal	O
damage	O
,	O
a	O
low	O
surgical	O
trachea	O
site	O
,	O
repetitive	O
neck	O
movement	O
,	O
radiotherapy	other-medical
,	O
or	O
prolonged	O
intubation	O
.	O

RTI-120	O
has	O
a	O
short	O
duration	O
of	O
action	O
,	O
along	O
with	O
other	O
p-	O
methyl	O
substituted	O
phenyltropanes	O
such	O
as	O
RTI-150	O
,	O
RTI-171	O
and	O
RTI-199	O
,	O
giving	O
it	O
a	O
more	O
similar	O
pharmacological	O
profile	O
to	O
cocaine	other-medical
compared	O
to	O
longer	O
acting	O
analogues	O
like	O
RTI-121	O
and	O
RTI-177	O
.	O

However	O
,	O
most	O
data	O
remain	O
proprietary	O
and	O
thus	O
reviews	O
on	O
the	O
expanded	O
clinical	O
potential	O
for	O
drugs	O
like	O
aprepitant	other-medical
range	O
from	O
optimistic	O
to	O
poor	O
.	O

For	O
instance	O
,	O
tamoxifen	other-medical
has	O
predominantly	O
antiestrogenic	O
effects	O
in	O
the	O
breasts	O
but	O
predominantly	O
estrogenic	O
effects	O
in	O
the	O
uterus	O
and	O
liver	O
.	O

In	O
1978	O
,	O
the	O
Eye	O
and	O
Ear	O
was	O
the	O
site	O
of	O
a	O
pioneering	O
operation	O
to	O
install	O
the	O
world	O
's	O
first	O
multi-channel	other-medical
cochlear	other-medical
implant	other-medical
(	O
Bionic	other-medical
Ear	other-medical
)	O
,	O
developed	O
by	O
Graeme	O
Clark	O
.	O

As	O
lorazepam	other-medical
can	O
have	O
paradoxical	O
effects	O
,	O
haloperidol	other-medical
is	O
sometimes	O
given	O
at	O
the	O
same	O
time	O
.	O

Gabapentin	other-medical
may	O
reduce	O
symptoms	O
associated	O
with	O
neuropathic	O
pain	O
or	O
fibromyalgia	O
in	O
some	O
people	O
.	O

Analgesics	other-medical
are	O
frequently	O
used	O
in	O
combination	O
,	O
such	O
as	O
the	O
paracetamol	other-medical
and	O
codeine	other-medical
preparations	other-medical
found	O
in	O
many	O
non-prescription	O
pain	O
relievers	O
.	O

Ritonavir	other-medical
is	O
manufactured	O
as	O
Norvir	other-medical
by	O
AbbVie	O
,	O
Inc	O
..	O

Approximately	O
5	O
%	O
of	O
the	O
patients	O
who	O
have	O
taken	O
hydralazine	other-medical
over	O
long	O
periods	O
of	O
time	O
and	O
in	O
high	O
doses	O
have	O
shown	O
DIL	O
-like	O
symptoms	O
.	O

Natalizumab	other-medical
is	O
considered	O
highly	O
effective	O
in	O
terms	O
of	O
relapse	O
rate	O
reduction	O
and	O
halting	O
disability	O
progression	O
,	O
however	O
,	O
it	O
is	O
considered	O
a	O
second-line	O
treatment	O
because	O
of	O
the	O
risk	O
of	O
adverse	O
side-effects	O
.	O

Attempts	O
to	O
actively	O
expel	O
water	O
from	O
the	O
airway	O
by	O
abdominal	O
thrusts	O
,	O
Heimlich	other-medical
maneuver	other-medical
or	O
positioning	O
head	O
downwards	O
should	O
be	O
avoided	O
as	O
there	O
is	O
no	O
obstruction	O
by	O
solids	O
,	O
and	O
they	O
delay	O
the	O
start	O
of	O
ventilation	O
and	O
increase	O
the	O
risk	O
of	O
vomiting	O
,	O
with	O
a	O
significantly	O
increased	O
risk	O
of	O
death	O
,	O
as	O
the	O
a	O
spiration	O
of	O
stomach	O
contents	O
is	O
a	O
common	O
complication	O
of	O
resuscitation	O
efforts	O
.	O

The	O
live	O
attenuated	O
BCG	other-medical
vaccine	O
developed	O
against	O
tuberculosis	O
has	O
been	O
shown	O
to	O
have	O
strong	O
beneficial	O
effects	O
on	O
the	O
ability	O
to	O
combat	O
non-	O
tuberculosis	O
infections	O
.	O

Naltrexone	other-medical
monthly	O
IM	O
injections	O
received	O
FDA	O
approval	O
in	O
2010	O
,	O
for	O
the	O
treatment	O
of	O
opioid	other-medical
dependence	O
in	O
abstinent	O
opioid	other-medical
users	O
.	O

Baird	O
,	O
was	O
instrumental	O
in	O
gaining	O
approval	O
for	O
the	O
use	O
of	O
RU-486	other-medical
in	O
the	O
UK	O
as	O
an	O
emergency	O
contraceptive	O
or	O
'morning	O
after	O
pill	O
'	O
.	O

Different	O
strengths	O
,	O
doses	O
and	O
routes	O
of	O
administration	O
of	O
epinephrine	other-medical
are	O
used	O
.	O

The	O
history	O
of	O
opium	other-medical
in	O
China	O
began	O
with	O
the	O
use	O
of	O
opium	other-medical
for	O
medicinal	O
purposes	O
during	O
the	O
7th	O
century	O
.	O

A	O
high-quality	O
ELISA	other-medical
test	O
for	O
human	O
recombinant	O
erythropoietin	O
is	O
now	O
available	O
,	O
and	O
recently	O
the	O
first	O
Mass	other-medical
Spectral	other-medical
Confirmation	other-medical
method	O
to	O
detect	O
use	O
of	O
human	other-medical
recombinant	other-medical
erythropoietin	other-medical
(	O
rhEPO	other-medical
)	O
in	O
horses	O
or	O
any	O
species	O
was	O
developed	O
.	O

Very	O
large	O
intakes	O
of	O
fish	other-medical
oil	other-medical
/	O
omega-3	other-medical
fatty	O
acids	O
may	O
increase	O
the	O
risk	O
of	O
hemorrhagic	O
(	O
bleeding	O
)	O
stroke	O
.	O
''	O

In	O
addition	O
,	O
there	O
is	O
also	O
a	O
small	O
risk	O
of	O
cross-reactivity	O
in	O
patients	O
having	O
experienced	O
angioedema	O
with	O
ACE	other-medical
inhibitor	other-medical
therapy	O
.	O

Nonsteroidal	other-medical
anti-inflammatory	other-medical
drugs	other-medical
(	O
NSAIDs	other-medical
)	O
such	O
as	O
ibuprofen	other-medical
and	O
naproxen	other-medical
are	O
effective	O
in	O
relieving	O
the	O
pain	O
of	O
primary	other-medical
dysmenorrhea	other-medical
.	O

The	O
initial	O
discovery	O
of	O
spirorenone	other-medical
was	O
deemed	O
a	O
great	O
success	O
,	O
as	O
no	O
compound	O
with	O
greater	O
antimineralocorticoid	O
activity	O
had	O
been	O
developed	O
since	O
spironolactone	O
in	O
1957	O
.	O

In	O
overdose	O
propranolol	other-medical
is	O
associated	O
with	O
seizures	O
.	O

If	O
antibiotics	O
are	O
used	O
,	O
a	O
narrow-spectrum	O
antibiotic	O
like	O
amoxicillin	other-medical
is	O
generally	O
recommended	O
,	O
as	O
broad-spectrum	O
antibiotics	O
may	O
be	O
associated	O
with	O
more	O
adverse	O
events	O
.	O

Preparations	O
made	O
from	O
blistering	O
beetles	O
have	O
been	O
used	O
since	O
ancient	O
times	O
as	O
an	O
aphrodisiac	other-medical
,	O
possibly	O
because	O
their	O
physical	O
effects	O
were	O
perceived	O
to	O
mimic	O
those	O
of	O
sexual	O
arousal	O
,	O
and	O
because	O
they	O
can	O
cause	O
prolonged	O
erection	O
or	O
priapism	O
in	O
men	O
.	O

Enoxaparin	other-medical
binds	O
to	O
and	O
potentiates	O
antithrombin	O
(	O
a	O
circulating	O
anticoagulant	O
)	O
to	O
form	O
a	O
complex	O
that	O
irreversibly	O
inactivates	O
clotting	O
factor	O
Xa	O
.	O

A	O
stroke	O
is	O
caused	O
by	O
hypoperfusion	O
(	O
lack	O
of	O
oxygen	O
)	O
to	O
an	O
area	O
of	O
the	O
brain	O
,	O
which	O
is	O
commonly	O
caused	O
by	O
thrombosis	other-medical
or	O
embolism	other-medical
.	O

Myocet	other-medical
is	O
another	O
non-pegylated	O
liposome	O
encapsulated	O
doxorubicin	O
citrate	O
complex	O
approved	O
for	O
use	O
in	O
combination	O
with	O
cyclophosphamide	O
in	O
metastatic	O
breast	O
cancer	O
patients	O
as	O
first	O
line	O
treatment	O
in	O
Europe	O
and	O
Canada	O
.	O

Generally	O
speaking	O
,	O
routine	O
measurement	O
of	O
C-peptide	O
as	O
a	O
measure	O
of	O
insulin	other-medical
production	O
is	O
not	O
recommended	O
unless	O
there	O
is	O
genuine	O
doubt	O
as	O
to	O
whether	O
someone	O
has	O
type	O
1	O
or	O
type	O
2	O
diabetes	O
.	O

Mary	O
Edison	O
died	O
at	O
age	O
29	O
on	O
August	O
9	O
,	O
1884	O
,	O
of	O
unknown	O
causes	O
:	O
possibly	O
from	O
a	O
brain	O
tumor	O
or	O
a	O
morphine	other-medical
overdose	O
.	O

However	O
,	O
religious	O
and	O
conservative	O
lobbying	O
groups	O
as	O
well	O
as	O
the	O
influence	O
of	O
neo-eugenicscreated	O
push	O
back	O
on	O
some	O
other	O
forms	O
of	O
birth	O
control	O
such	O
as	O
emergency	other-medical
contraception	other-medical
and	O
tubal	other-medical
ligation	other-medical
.	O

Velneperit	other-medical
(	O
S-2367	O
)	O
is	O
a	O
drug	O
developed	O
by	O
Shionogi	O
,	O
which	O
acts	O
as	O
a	O
potent	O
and	O
selective	O
antagonist	O
for	O
the	O
Neuropeptide	O
Y	O
receptor	O
Y5	O
.	O

In	O
2005	O
,	O
the	O
withdrawal	O
of	O
the	O
painkiller	other-medical
Vioxx	other-medical
was	O
followed	O
by	O
an	O
investigation	O
by	O
Deer	O
into	O
the	O
people	O
responsible	O
for	O
the	O
drug	O
's	O
introduction	O
.	O

In	O
about	O
10	O
%	O
of	O
cases	O
the	O
blood	other-medical
sugar	other-medical
is	O
not	O
significantly	O
elevated	O
(	O
``	O
euglycemic	O
diabetic	O
ketoacidosis	O
``	O
)	O
.	O

In	O
2001	O
,	O
Merck	O
commenced	O
the	O
APPROVe	O
(	O
Adenomatous	O
Polyp	O
PRevention	O
On	O
Vioxx	other-medical
)	O
study	O
,	O
a	O
three-year	O
trial	O
with	O
the	O
primary	O
aim	O
of	O
evaluating	O
the	O
efficacy	O
of	O
rofecoxib	other-medical
for	O
the	O
prophylaxis	O
of	O
colorectal	O
polyps	O
.	O

The	O
biggest	O
controversy	O
of	O
the	O
2012	O
Breeders	O
'	O
Cup	O
related	O
to	O
the	O
use	O
of	O
the	O
anti-bleeding	O
medication	O
Furosemide	other-medical
(	O
Lasix	other-medical
)	O
,	O
commonly	O
used	O
in	O
North	O
America	O
but	O
not	O
permitted	O
elsewhere	O
.	O

The	O
oral	O
antifungal	O
drug	O
Diflucan	other-medical
(	O
fluconazole	O
)	O
,	O
which	O
had	O
been	O
discovered	O
at	O
the	O
Sandwich	O
site	O
,	O
was	O
launched	O
in	O
1988	O
.	O

Pertaining	O
to	O
the	O
(	O
online	O
)	O
drug	O
market/trade	O
which	O
exists	O
in	O
Cambodia	O
,	O
more	O
recently	O
the	O
trade	O
took	O
on	O
its	O
international	O
intervention	O
in	O
which	O
officials	O
were	O
able	O
to	O
prevent	O
10,000	O
tablets	O
of	O
Codeine	other-medical
and	O
Valium	other-medical
being	O
sent	O
out	O
of	O
Cambodia	O
to	O
the	O
United	O
States	O
and	O
United	O
Kingdom	O
.	O

Methotrexate	other-medical
is	O
teratogenic	O
and	O
hence	O
is	O
not	O
advised	O
for	O
either	O
the	O
prospective	O
father	O
to	O
take	O
it	O
before	O
or	O
for	O
the	O
mother	O
to	O
take	O
it	O
before	O
or	O
during	O
pregnancy	O
(	O
pregnancy	O
category	O
X	O
)	O
and	O
for	O
a	O
period	O
after	O
birth	O
.	O

Caffeine	other-medical
has	O
also	O
been	O
shown	O
to	O
reduce	O
errors	O
made	O
by	O
shift	O
workers	O
.	O

Another	O
potential	O
immunotherapy	O
is	O
trastuzumab	other-medical
,	O
which	O
is	O
active	O
against	O
tumors	O
positive	O
for	O
Her2	O
/	O
neu	O
mutations	O
.	O

Salbutamol	other-medical
,	O
also	O
known	O
as	O
albuterol	O
and	O
marketed	O
as	O
Ventolin	other-medical
among	O
other	O
brand	O
names	O
,	O
is	O
a	O
medication	O
that	O
opens	O
up	O
the	O
medium	O
and	O
large	O
airways	O
in	O
the	O
lungs	O
.	O

It	O
acts	O
as	O
a	O
potent	O
serotonin	other-medical
receptor	O
agonist	O
with	O
similar	O
affinity	O
to	O
the	O
better-known	O
compound	O
25B-NBOMe	O
at	O
5-HT2A	O
and	O
5-HT2C	O
receptors	O
with	O
pKis	O
values	O
of	O
8.3	O
and	O
9.4	O
,	O
respectively	O
.	O

Idiopathic	O
ventricular	O
fibrillation	O
occurs	O
with	O
a	O
reputed	O
incidence	O
of	O
approximately	O
1	O
%	O
of	O
all	O
cases	O
of	O
out-of-hospital	O
arrest	O
,	O
as	O
well	O
as	O
3–9	O
%	O
of	O
the	O
cases	O
of	O
ventricular	O
fibrillation	O
unrelated	O
to	O
myocardial	O
infarction	O
,	O
and	O
14	O
%	O
of	O
all	O
ventricular	other-medical
fibrillation	other-medical
resuscitations	other-medical
in	O
patients	O
under	O
the	O
age	O
of	O
40	O
.	O